OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

Community Oncology Global Congress 2026

Donald Trump Nominates Heidi Overton as Next FDA Commissioner

From the Marathon 2024 to Olympus 2026: ELPIDA Climbs for Children with Cancer Around the World

Giannis Mountzios: A New ESMO Guide for Thoracic Cancer Care

ASCO 2026 Guideline: A Risk-Adapted Framework for Early HR-Positive, HER2-Negative Breast Cancer

ctDNA and MRD in NSCLC: Emerging Clinical Applications in the Immunotherapy Era

DART-PHASER: Daily Adaptive Salvage Radiotherapy in Prostate Cancer

Pancreatic Cancer FDA Approval Following Landmark Trial Led by Dana-Farber

Calculators

Khorana Score (Cancer-Associated VTE Risk)

Estimates venous thromboembolism (VTE) risk in ambulatory cancer patients using the validated Khorana score.

Khorana Score Points:

  • Very high-risk site (Stomach, Pancreas): +2
  • High-risk site (Lung, Lymphoma, Gynecologic, Bladder, Testicular): +1
  • Platelets ≥350 ×10⁹/L: +1
  • Hemoglobin <10 g/dL or ESA use: +1
  • WBC >11 ×10⁹/L: +1
  • BMI ≥35 kg/m²: +1

Risk Categories:

  • Low risk: 0 points
  • Intermediate risk: 1-2 points
  • High risk: ≥3 points